Expert clinical management of autoimmune hepatitis in the real world
Rodrigo Liberal(King's College - North Carolina), George Ν. Dalekos(University Hospital of Larissa), Marco Lenzi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), John M. Vierling(Baylor College of Medicine), Gideon M. Hirschfield(University Health Network), Raúl J. Andrade(Hospital Clínico Universitario Virgen de la Victoria), Annarosa Floreani(University of Padua), Ynto S. de Boer(Amsterdam University Medical Centers), Pietro Invernizzi(Azienda Ospedaliera San Gerardo), Dermot Gleeson(Sheffield Teaching Hospitals NHS Foundation Trust), Ansgar W. Lohse(Universität Hamburg), Guilherme Macedo(Hospital de São João), Piotr Milkiewicz(Medical University of Warsaw), Bart van Hoek(Leiden University Medical Center), Michael A. Heneghan(King's College Hospital NHS Foundation Trust)
Cited by 89
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k